drugset / Trial / NCT00844857

A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

NCT00844857

Phase 4 Completed 291 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. * Can this study drug make children with bipolar depression feel better? * Does this study drug work better than a placebo (sugar pill)? * Does this study drug cause side effects in children who take it? * Is this drug safe to use in children? (The study drug is a mixture of olanzapine and fluoxetine)

Timeline

Start
2009-04
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 25 mg Oral
Subject Fluoxetine Small molecule 50 mg Oral
Subject Olanzapine Small molecule 3 mg Oral
Subject Olanzapine Small molecule 6 mg Oral
Subject Olanzapine Small molecule 12 mg Oral

Indications